A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells

Biochemical Journal

Volumn 408, Issue 2, 2007, Pages 203-210

  Croucher, David R ^a,b   Saunders, Darren M ^b,c,d   Stillfried, Gillian E ^a   Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Plasminogen activator inhibitor type 1 (PAI 1); Plasminogen activator inhibitor type 2 (PAI 2); Serpin (serine protease inhibitor); Urokinase plasminogen activator (uPA); Very low density lipoprotein receptor (VLDLr)

Indexed keywords

BINDING SITES; BIOLOGICAL ORGANS; ENZYME INHIBITION; TUMORS;

CELL SIGNALLING; CELL SURFACE; PLASMINOGENS; SERINE PROTEASE INHIBITORS; UROKINASE PLASMINOGEN ACTIVATORS;

CELL PROLIFERATION;

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; HUMAN; HUMAN CELL; KINETICS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECEPTORS, LDL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 36749093009     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070767     Document Type: Article

References (43)

1. Dano, K., Romer, J., Nielsen, B. S., Bjorn, S., Pyke, C., Rygaard, J. and Lund, L. R. (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107, 120-127
2. Blasi, F. (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the uPA-uPAR-PAI-1 system Thromb. Haemostasis 82, 298-304
3. Han, B., Nakamura, M., Mori, I., Nakamura, Y. and Kakudo, K. (2005) Urokinase-type plasminogen activator system and breast cancer. Oncol. Rep. 14, 105-112
4. Kjoller, L. (2002) The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 383, 5-19
5. Reuning, U., Magdolen, V., Hapke, S. and Schmitt, M. (2003) Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol. Chem. 384, 1119-1131
6. Liu, D., Aguirre Ghiso, J., Estrada, Y. and Ossowski, L. (2002) EGFR is a transducer of the urokinase receptor initiated signal that is reguired for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457
7. Strickland, D. K., Gonias, S. L. and Argraves, W. S. (2002) Diverse roles for the LDL receptor family. Trends Endocrinol. Metab. 13, 66-74
8. Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C., Coughlin, P. B., Gettins, P. G., Irving, J. A., Lomas, D. A., Luke, C. J., Moyer, R. W. et al. (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293-33296
9. Kruithof, E. K., Baker, M. S. and Bunn, C. L. (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86, 4007-4024
10. Al-Ejeh, F., Croucher, D. and Ranson, M. (2004) Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp. Cell Res. 297, 259-271
11. Ellis, V., Wun, T. C., Behrendt, N., Ronne, E. and Dano, K. (1990) Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 265, 9904-9908
12. Duffy, M. J. (2004) The urokinase plasminogen activator system: role in malignancy. Curr. Pharm. Des. 10, 39-49
13. Weigelt, B., Peterse, J. L. and van't Veer, L. J. (2005) Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602
14. Duffy, M. J. and Duggan, C. (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37, 541-548
15. Liu, G., Shuman, M. A. and Cohen, R. L. (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer. 60, 501-506
16. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D. and Foidart, J. M. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928
17. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brunner, N., Janicke, F., Meijer-van Gelder, M. E., Henzen-Logmans, S. C. et al. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636-643
18. Argraves, K. M., Battey, F. D., MacCalman, C. D., McCrae, K. R., Gafvels, M., Kozarsky, K. F., Chappell, D. A., Strauss, 3rd, J. F. and Strickland, D. K. (1995) The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. Biol. Chem. 270, 26550-26557
19. Croucher, D., Saunders, D. N. and Ranson, M. (2006) The urokinase-PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. J. Biol. Chem. 281, 10206-10213
20. Herz, J., Clouthier, D. E. and Hammer, R. E. (1992) LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71, 411-421
21. Kounnas, M. Z., Henkin, J., Argraves, W. S. and Strickland, D. K. (1993) Low density lipoprotein receptor-related protein/α2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J. Biol. Chem. 268, 21862-21867
22. Nykjaer, A., Kjoller, L., Cohen, R. L., Lawrence, D. A., Garni-Wagner, B. A., Todd, 3rd, R. F., van Zonneveld, A. J., Gliemann, J. and Andreasen, P. A. (1994) Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic α2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J. Biol. Chem. 269, 25668-25676
23. Rodenburg, K. W., Kjoller, L., Petersen, H. H. and Andreasen, P. A. (1998) Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem. J. 329, 55-63
24. Stefansson, S., Muhammad, S., Cheng, X. F., Battey, F. D., Strickland, D. K. and Lawrence, D. A. (1998) Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J. Biol. Chem. 273, 6358-6366
25. Webb, D. J., Nguyen, D. H., Sankovic, M. and Gonias, S. L. (1999) The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274, 7412-7420
26. Herz, J. and Strickland, D. K. (2001) LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108, 779-784
27. Nguyen, D. H., Catling, A. D., Webb, D. J., Sankovic, M., Walker, L. A., Somlyo, A. V., Weber, M. J. and Gonias, S. L. (1999) Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146, 149-164
28. Webb, D. J., Thomas, K. S. and Gonias, S. L. (2001) Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J. Cell Biol. 152, 741-752
29. Degryse, B., Neels, J. G., Czekay, R. P., Aertgeerts, K., Kamikubo, Y. and Loskutoff, D. J. (2004) The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem. 279, 22595-22604
30. Ranson, M., Andronicos, N. M., O'Mullane, M. J. and Baker, M. S. (1998) Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br. J. Cancer. 77, 1586-1597
31. Ruiz, J., Kouiavskaia, D., Migliorini, M., Robinson, S., Saenko, E. L., Gorlatova, N., Li, D., Lawrence, D., Hyman, B. T., Weisgraber, K. H. and Strickland, D. K. (2005) The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46, 1721-1731
32. Aertgeerts, K., De Bondt, H. L., De Ranter, C. J. and Declerck, P. (1995) Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struc. Biol. 2, 891-897
33. Jankova, L., Harrop, S. J., Saunders, D. N., Andrews, J. L., Bertram, K. C., Gould, A. R., Baker, M. S. and Curmi, P. M. (2001) Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop. J. Biol. Chem. 276, 43374-43382
34. Huber, R. and Carrell, R. W. (1989) Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry 28, 8951-8966
35. Fisher, C., Beglova, N. and Blacklow, S. C. (2006) Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol. Cell. 22, 277-283
36. Hussain, M. M., Strickland, D. K. and Bakillah, A. (1999) The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 19, 141-172
37. Jensen, G. A., Andersen, O. M., Bonvin, A. M., Bjerrum-Bohr, I., Etzerodt, M., Thogersen, H. C., O'Shea, C., Poulsen, F. M. and Kragelund, B. B. (2006) Binding site structure of one LRP-RAP complex: implications for a common ligand-receptor binding motif. J. Mol. Biol. 362, 700-716
38. Stefansson, S. and Lawrence, D. A. (1996) The serpin PAI-1 inhibits cell migration by blocking integrin αVβ3 binding to vitronectin. Nature 383, 441-443
39. Mikhailenko, I., Considine, W., Argraves, K. M., Loukinov, D., Hyman, B. T. and Strickland, D. K. (1999) Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms. J. Cell Sci. 112, 3269-3281
40. Heegaard, C. W., Simonsen, A. C., Oka, K., Kjoller, L., Christensen, A., Madsen, B., Ellgaard, L., Chan, L. and Andreasen, P. A. (1995) Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J. Biol. Chem. 270, 20855-20861
41. Kasza, A., Petersen, H. H., Heegaard, C. W., Oka, K., Christensen, A., Dubin, A., Chan, L. and Andreasen, P. A. (1997) Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and α2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein. Eur. J. Biochem. 248, 270-281
42. Skeldal, S., Larsen, J. V., Pedersen, K. E., Petersen, H. H., Egelund, R., Christensen, A., Jensen, J. K., Gliemann, J. and Andreasen, P. A. (2006) Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. FEBS J. 273, 5143-5159
43. Horn, I. R., van den Berg, B. M., Moestrup, S. K., Pannekoek, H. and van Zonneveld, A. J. (1998) Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Thromb. Haemostasis 80, 822-828